

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – July 8, 2020 @ 4:00pm

OHCA Webinar

Register for the meeting here:

<https://odot.webex.com/odot/onstage/g.php?MTID=e9d464f216e5800f073f4c346d55f26c8>

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Skrepnek

Telephone Conference Participants

DUR Board Members:

Dr. Stephen Anderson –

participating via Webex Teleconference

Dr. Jennifer de los Angeles –

participating via Webex Teleconference

Ms. Jennifer Boyett –

participating via Webex Teleconference

Dr. Markita Broyles –

participating via Webex Teleconference

Dr. Theresa Garton –

participating via Webex Teleconference

Dr. Megan Hanner –

participating via Webex Teleconference

Dr. Lynn Mitchell –

participating via Webex Teleconference

Dr. John Muchmore –

participating via Webex Teleconference

Dr. Lee Muñoz –

participating via Webex Teleconference

Dr. James Osborne –

participating via Webex Teleconference

Public Access to Meeting via Webex:

Register at:

<https://odot.webex.com/odot/onstage/g.php?MTID=e9d464f216e5800f073f4c346d55f26c8>

Or join by phone:

Dial: +1-415-655-0002

Event number: 133 269 7414

Event password: 20200608

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 10, 2020 DUR Minutes – Vote
- B. June 10, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Nawaz, Dr. Adams, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix B

- A. Pharmacy Helpdesk Activity for June 2020
- B. Medication Coverage Activity for June 2020
- C. Chronic Medication Adherence Program Update

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Wakix® (Pitolisant) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Secuado® (Asenapine Transdermal Patch) and Caplyta™ (Lumateperone Capsule) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Absorica LD™ (Isotretinoin Capsule), Amzeeq™ (Minocycline 4% Topical Foam), Aprizio Pak™ (Lidocaine/Prilocaine 2.5%/2.5% Kit), Caldolor® (Ibuprofen Injection), Exservan™ (Riluzole Oral Film), Metronidazole 1% Gel, Noritate® (Metronidazole 1% Cream), Procysbi® [Cysteamine Delayed-Release (DR) Granule], Pyridostigmine 30mg Tablet, Quzyttir™ (Cetirizine Injection), Relafen™ DS (Nabumetone Tablet), Slynd™ (Drospirenone Tablet), Talicia® (Omeprazole/ Amoxicillin/ Rifabutin Capsule), and Tirosint® (Levothyroxine Capsule) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Iluvien® (Fluocinolone Intravitreal Implant), Ozurdex® (Dexamethasone Intravitreal Implant), and Retisert® (Fluocinolone Intravitreal Implant) – See Appendix F

- A. Introduction
- B. Cost Comparison
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Isturisa® (Osilodrostat) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Baxley, Dr. Muchmore, Chairman:

10. 30-Day Notice to Prior Authorize Koselugo™ (Selumetinib), Pemazyre™ (Pemigatinib), and Qinlock™ (Ripretinib) – See Appendix H

- A. Introduction
- B. Market News and Updates
- C. Product Summaries
- D. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Action Item – Annual Review of Topical Corticosteroids – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Corticosteroids
- C. Prior Authorization of Topical Corticosteroids
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Topical Corticosteroids

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

12. Annual Review of Opioid Analgesics and Opioid Medication Assisted Treatment (MAT) Medications and 30-Day Notice to Prior Authorize Tramadol 100mg Tablet – See Appendix J

- A. Current Prior Authorization Criteria
- B. Medicaid Drug Rebate Program
- C. Utilization of Opioid Analgesics and MAT Medications
- D. Prior Authorization of Opioid Analgesics and MAT Medications
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics
- H. Utilization Details of MAT Medications

Non-Presentation Item; Questions Only:

13. Annual Review of Amyloidosis Medications – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Amyloidosis Medications
- C. Prior Authorization of Amyloidosis Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix L

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**15. Future Business* (Upcoming Product and Class Reviews)
*No meeting scheduled for August 2020.***

- A. Synagis® (Palivizumab)
- B. Sickle Cell Medications and Beta Thalassemia Medications
- C. Breast Cancer Medications
- D. Prostate Cancer Medications

**Future business subject to change.*

16. Adjournment